Roche Holding has signed a $548 million agreement with Polyphor for the development and commercialization of experimental antibiotic POL7080 to fight drug-resistant infections in hospitals. Under the deal, Roche will pay $38.4 million upfront. In addition, Polyphor is entitled to receive double-digit royalties on product sales.

Full Story:

Related Summaries